Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Constance King"'
Autor:
Mark S. Marshall, David Barda, Richard Beckmann, Wayne Blosser, Jack Dempsey, Darlene Barnard, Samuel McNeely, H. Bruce Diaz, Constance King
Supplementary Table S3. Induction of DNA damage by LY2606368 is not caused by caspase-dependent apoptotic DNA fragmentation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42e7750498664489cd3e68278fcc45b3
https://doi.org/10.1158/1535-7163.22502026
https://doi.org/10.1158/1535-7163.22502026
Autor:
Mark S. Marshall, David Barda, Richard Beckmann, Wayne Blosser, Jack Dempsey, Darlene Barnard, Samuel McNeely, H. Bruce Diaz, Constance King
This file contains all supplementary figures: Figure S1. LY2606368 is an ATP competitive inhibitor of CHK1. Figure S2. LY2606368 is a potent catalytic and phenotypic inhibitor of CHK1. Figure S3. LY2606368 inhibits DNA damage-dependent autophosphoryl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89199eaf9f39384d941a59fe88535101
https://doi.org/10.1158/1535-7163.22502038
https://doi.org/10.1158/1535-7163.22502038
Autor:
Mark S. Marshall, David Barda, Richard Beckmann, Wayne Blosser, Jack Dempsey, Darlene Barnard, Samuel McNeely, H. Bruce Diaz, Constance King
This file contains the supplementary Materials and Methods section, supplementary references, legends for all supplementary figures and descriptions of all of the supplementary tables.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b32177a839209ff688d746d55370424b
https://doi.org/10.1158/1535-7163.22502035
https://doi.org/10.1158/1535-7163.22502035
Autor:
Mark S. Marshall, David Barda, Richard Beckmann, Wayne Blosser, Jack Dempsey, Darlene Barnard, Samuel McNeely, H. Bruce Diaz, Constance King
Supplementary Table S4. LY2606368-dependent chromosome fragmentation is not caused by caspase-dependent apoptosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1289eae9da74d6906d46049bde3b3bcb
https://doi.org/10.1158/1535-7163.22502023.v1
https://doi.org/10.1158/1535-7163.22502023.v1
Autor:
Mark S. Marshall, David Barda, Richard Beckmann, Wayne Blosser, Jack Dempsey, Darlene Barnard, Samuel McNeely, H. Bruce Diaz, Constance King
Supplementary Table S1. Protein kinases tested for inhibition by LY2606368
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36523100601b57418ac5f58fd8523c58
https://doi.org/10.1158/1535-7163.22502032
https://doi.org/10.1158/1535-7163.22502032
Autor:
Mark S. Marshall, David Barda, Richard Beckmann, Wayne Blosser, Jack Dempsey, Darlene Barnard, Samuel McNeely, H. Bruce Diaz, Constance King
upplementary Table S2. Protein kinases sensitive to LY2606368 with an IC50 less than 10,000 nM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af2c7819d80f9023872e2af1c37e620e
https://doi.org/10.1158/1535-7163.22502029
https://doi.org/10.1158/1535-7163.22502029
Autor:
Constance King, David Anthony Barda, Mark S. Marshall, H. Bruce Diaz, Darlene S. Barnard, Bonita D. Jones, Gregory P. Donoho, Richard P. Beckmann, Teresa F. Burke
Publikováno v:
Investigational New Drugs. 34:49-60
Pharmacological inhibition of CHK1 in the absence of p53 functionality leads to abrogation of the S and G2/M DNA damage checkpoints. We report the preclinical therapeutic activity of LY2603618 (CHK1 inhibitor) at inhibiting CHK1 activation by gemcita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::544e6cd03ce7a15575cf14dace2a5626
https://doi.org/10.1007/s10637-015-0310-y
https://doi.org/10.1007/s10637-015-0310-y
Autor:
Wayne Blosser, Constance King, David Anthony Barda, Jack A. Dempsey, Darlene S. Barnard, Richard P. Beckmann, Samuel McNeely, Mark S. Marshall, H. Bruce Diaz
Publikováno v:
Molecular Cancer Therapeutics. 14:2004-2013
CHK1 is a multifunctional protein kinase integral to both the cellular response to DNA damage and control of the number of active replication forks. CHK1 inhibitors are currently under investigation as chemopotentiating agents due to CHK1's role in e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dcade60a1b1a506e5940fba13c8f1a1
https://doi.org/10.1158/1535-7163.mct-14-1037
https://doi.org/10.1158/1535-7163.mct-14-1037
Autor:
Constance King, Darlene S. Barnard, David Anthony Barda, Mark S. Marshall, Wayne Blosser, David K. Clawson, Henry Bruce Diaz, Karen Cox, Sherry Guo
Publikováno v:
Investigational New Drugs. 32:213-226
Interference with DNA damage checkpoints has been demonstrated preclinically to be a highly effective means of increasing the cytotoxicity of a number of DNA-damaging cancer therapies. Cell cycle arrest at these checkpoints protects injured cells fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60229d45e833c0483c45442365c4e3f9
https://doi.org/10.1007/s10637-013-0036-7
https://doi.org/10.1007/s10637-013-0036-7
Autor:
Christoph Reinhard, Constance King, Mark A. Castanares, Gregory P. Donoho, Ricardo Martinez, Andrew Capen, Richard P. Beckmann, Susan E. Pratt, Sean Buchanan, Wenjuan Wu, Yan Ding, Aimee Lin, Jennifer R. Stephens, Philip W. Iversen
Publikováno v:
Cancer Research. 78:336-336
Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, is diagnosed in approximately 15% of all breast cancer patients and characterized by high level of genomic instability, defects in DNA damage response (DDR) and incre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fa5b08a15a4f191ad69ca6d5acf1dee
https://doi.org/10.1158/1538-7445.am2018-336
https://doi.org/10.1158/1538-7445.am2018-336